Viatris & United States — Food and Drug Administration

Viatris: Viatris is facing a class action lawsuit due to allegedly misleading investors about the impact of a US Food and Drug Administration warning letter on its Indore, India facility, which led to a significant stock price decline.

United States — Food and Drug Administration: The United States — Food and Drug Administration issued a warning letter regarding Viatris' Indore, India facility, which is central to the class action allegations.

Viatris: Viatris is the defendant in a class action securities lawsuit due to alleged misrepresentation of the impact of a US Food and Drug Administration warning letter on its Indore, India facility, leading to a significant stock price decline.

Viatris: Viatris is facing a securities class action lawsuit for allegedly misleading investors about the impact of a failed inspection at its Indore, India facility and a Warning Letter from the U.S. Food and Drug Administration. This led to a significant drop in its stock price.

Viatris: Viatris is the defendant in a class action lawsuit alleging that it made materially false and misleading statements regarding the impact of a US Food and Drug Administration warning letter on its financials.

Viatris: Viatris is facing a securities fraud lawsuit due to alleged misrepresentations regarding the operational condition of its Indore, India facility and the subsequent financial impact of a U.S. Food and Drug Administration Warning Letter.